Vaccination can protect adults' life course from infectious diseases

VThe qualifications are an essential part of infant and child care, offering protection from diseases such as diphtheria, tetanus, pneumonia, and polio, diseases that have injured thousands of US children each year or killed thousands of people. worldwide. Sometimes it is forgotten that adults could benefit from vaccines. In order to prevent unnecessary deaths and to improve public health, the United States and other countries need to take the concept of lifetime vaccination more seriously, an approach to ensure effective immunization programs for people at risk. all ages and stages of life.

In the 2017-2018 influenza season, only 37% of adults in the United States were vaccinated against influenza, a decrease of 6% from the previous season, while the Control and Prevention Centers suggest vaccination as the best approach to influenza. to avoid infection. . Influenza occurs hard and fever can be treated with fluids and breaks: Among the 49 million Americans who came with flu during the 2017-2018 season, up to 959,000 were needed to go into hospital and 79,400 died.

Vaccines can prevent other diseases that are common in adults. The Washington University Institute of Metrics and Health Evaluation estimates that lower respiratory infections (including pneumonia and influenza) occurred in 2017 to over 1.5 million people aged 50 and over worldwide, particularly in low-income countries, t and account lost 23 million years of life. There are very few deaths in herpes zoster (the virus causing scandals), but it is a major factor in reducing productivity and affecting independent daily life.

Notice

This ongoing burden on preventable diseases grows in the absence of a global global policy on adult immunization. The World Health Organization has taken an important step by issuing a global influenza strategy, which I hope will provide a pathway to stronger country-to-country capability for the handling and detection of diseases, including emerging infections. over the flu.

As well as creating personal suffering, the avoidance of vaccination has economic consequences. In 2015, flu, pneumonia, and scandals cost the US more than $ 8.4 billion through lost treatment and productivity costs.

The problem of low vaccination rates among adults is not limited to the United States. It is a global phenomenon. Fewer than half of countries publicly recommend that older adults are vaccinated against influenza, and that rates of influenza vaccination among adults over 65 years of age are in countries that are part of the OECD. and Economic Development from as low as 2.8 per cent in Estonia to 84 as high as 84 percent in Korea.

Middle and low income countries are less likely to include adult vaccination than high income countries. With limited resources and weaker health systems, these countries focus on other priorities. In addition, individuals do not always see or have access to the value of vaccines.

Insert lifetime vaccination. It incorporates the simple fact that the risk of building diseases continues in recent years and in old age. But only a few countries, such as the United States, the UK and Australia, have taken a lifetime vaccination and many have had very few conversations.

There are common barriers to adult vaccination from concerns about the funding and competitiveness of health priorities to the lack of broad evidence and a coordinated global program to ensure the delivery of adult vaccines. An analysis of low income and middle income countries from the International Vaccine Access Center, the organization I work with, shows that they have few flu or pneumonia vaccines for adults. Clinicians and other healthcare professionals may be reluctant to recommend vaccines to adults, perhaps due to lack of incentives and concerns about cost, efficiency and safety.

Life course vaccination is urgently needed, taking into account the rapid growth in the number of older adults around the world. The UN reports that the global population in excess of 60 will be more than double between 2017 and 2050, growing to over 2 billion people. In adults over 70 years of age, the fifth cause of death in 2017 was lower respiratory infections that could be prevented from the vaccine and pneumococcal pneumonia. global surveillance to measure the extent of preventable in-adult deaths. seriously deficient.

As people stay longer and stay in the workforce longer, vaccines increase productivity. In addition, many older adults outside the workforce give attention to grandchildren, enabling working-age parents to continue working.

Immunization programs covering the life span create an infrastructure to respond quickly and effectively to emergencies, pandemics, and outbreaks. These programs have another welcome by-product: connecting people with the healthcare system enables people to diagnose and treat other health problems and to advise on healthy lifestyles.

Despite the recognition of lifetime immunization value, many countries are slow to recommend and fund vaccines for adults even when there are policy proposals. Many high-income countries and some middle-income countries recommend adult vaccination against pneumonia, for example, but coverage is low.

The emphasis on childhood immunization over the last decade, although much needed, is a small focus due to current demographic changes. The technical community, including partners such as the WHO, infectious disease experts, economists, researchers, and the healthy aging community, continues to provide advice on lifetime vaccination for countries that are consistent. or comprehensive. The lack of global recommendations for countries at the various stages of developing the message, of course, launches the importance of adult vaccines. Even in low-resource settings, there is a lot of work to be done to look at the evidence, to establish platforms to deliver immunization care and preventive health care, and to integrate into other investments in the health system.


World health leaders can no longer ignore this issue. Acceptance of adult immunization and lifetime vaccination as a preventative measure must be a political priority and a center for global health policy makers now working on a new vision and strategy for vaccines and immunizations. over the next decade. Just as a global movement has supported and funded global youth vaccination, a similar one is needed to create momentum for adult and life-cycle vaccination.

The growth of these demographic changes and the importance of preventing infectious diseases among older adults is growing. The International Council for Adult Immunization, composed of experts in the areas of healthy aging, infectious disease, economics, and social science, is hosted by the Johns Hopkins Public Health School Bloomberg, synthesising the available data on these trends. and health, the economy, and the social consequences of aging vaccines. On the basis of this work, the group will seek global recommendations from the World Health Organization and healthy aging organizations on the actions that countries need to take to integrate immunization planning into wider health strategies. These proposals should aim to increase the uptake of vaccines for adults, particularly in countries where older age groups are already above the younger age group population and in many countries where this is to happen. early.

The scope of this work must go beyond influenza, pneumonia, and scandals to cover potential vaccines against HIV, tuberculosis, malaria, Ebola, respiratory syncytial virus, and cytomegalovirus. Vaccines for infections that occur commonly in healthcare settings, for example Clostridium difficile and Staphylococcus, must also be noted.

The WHO has confirmed that a decade of aging will be healthy in 2021 to 2030. Sincerity vaccination will help life course in countries around the world to do so. And with a growing adult population in most parts of the world, it is a necessity.

Lois Privor-Dumm is a director of policy, advocacy and communications for the International Vaccine Access Center Bloom Hopkins Public Health School Bloomberg and White Paper author the need for a lifetime vaccination as part of a thought leadership series initiated by the. t International Federation of Manufacturers and Pharmaceutical Associations promoting global reflection on the future of immunization.

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.